Zuga Matt 4

What Happened
Zuga Matt, CFO & Chief Business Officer of Acumen Pharmaceuticals (ABOS), was granted two compensation awards on January 16, 2026: 99,133 restricted stock units (RSUs) and 148,700 derivative (option-type) awards. Both grants were reported at $0.00 per share (no cash purchase). Combined, 247,833 shares are subject to these awards; they are compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-01-16; Transaction type/code: A (award/grant); reported price: $0.00 per share.
• Awards reported: 99,133 RSUs (F1) and 148,700 derivative/option-based awards (F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting/conditions (from footnotes):
  • F1 (RSUs): Each RSU converts to one share; vests in three equal annual installments beginning one year after grant, subject to continuous service.
  • F2 (Derivative/option): Vests in 48 equal monthly installments (fully vested on the fourth anniversary), subject to continuous service.
• Filing date: 2026-01-21. The Form 4 was filed more than two business days after the Jan 16 transaction (filed Jan 21), so the filing appears late, which reduces near-term transparency for investors.

Context
RSUs represent a contingent right to receive shares upon vesting, and the derivative award appears to be an option-like grant that vests monthly over four years—both are common executive compensation vehicles. These awards are compensation-related and not direct purchases (they do not necessarily signal the insider buying or selling in the open market). A late Form 4 filing does not change the award terms but is a lapse in timely disclosure that some investors monitor.